FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma

specific

Endometrial endometrioid adenocarcinoma exhibiting more than 50% solid non-glandular, non-squamous growth.

Centers

Active Trials

—

Cancer Funding

Top Centers for FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma(18)

Ranked by research excellence score (trials · grants · publications). Methodology →

#	Center	Active Trials	Cancer Funding	Score
1	Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive	—	—	52.8
2	Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive	—	—	52.8
3	The University of Texas MD Anderson Cancer CenterHouston, TX NCI Comprehensive	—	—	52.8
4	Duke Cancer InstituteDurham, NC NCI Comprehensive	—	—	52.8
5	The University of Chicago Medicine Comprehensive Cancer CenterChicago, IL NCI Comprehensive	—	—	52.8
6	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive	—	—	52.8
7	University of Colorado Cancer CenterAurora, CO NCI Comprehensive	—	—	52.8
8	Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive	—	—	52.8
9	University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive	—	—	52.8
10	Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive	—	—	52.8
11	Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical	—	—	52.8
12	The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive	—	—	52.8
13	Dartmouth Cancer CenterLebanon, NH NCI Comprehensive	—	—	52.8
14	University of Illinois Cancer CenterChicago, IL	—	—	52.8
15	University of New Mexico Comprehensive Cancer CenterAlbuquerque, NM NCI Comprehensive	—	—	52.8
16	Cancer Center at IllinoisUrbana, IL	—	—	52.8
17	University of Cincinnati Cancer CenterCincinnati, OH	—	—	52.8
18	Louisiana Cancer Research CenterNew Orleans, LA	—	—	52.8

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →